Personalis, Inc. (04X.SG)
| Previous close | 17.25 |
| Open | 14.18 |
| Bid | 16.07 x N/A |
| Ask | 16.66 x N/A |
| Day's range | 13.94 - 14.94 |
| 52-week range | 1.17 - 14.94 |
| Volume | |
| Avg. volume | 117 |
| Market cap | 727.422M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings date | 31 Oct 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
FREMONT, Calif., August 29, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton New York.
- Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif., August 24, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, between the dates of May 15, 2023 and August 15, 2023, non-qualified stock options to purchase an aggregate of 43,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 24,500 shares of its common stock to sixteen new employees under Personalis’ 2020 Inducement Plan.
- Business Wire
Personalis Reports Second Quarter 2023 Financial Results
FREMONT, Calif., August 08, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights.
